Shawnte M. Mitchell's New Role at Olema Oncology
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering biopharmaceutical firm focused on targeting therapies for breast cancer, is excited to announce a significant addition to its executive team: Shawnte M. Mitchell, J.D., has been appointed as the new Chief Legal Officer and Corporate Secretary.
Welcoming a Seasoned Professional
Shawnte brings to Olema 20 years of experience in the healthcare and life sciences sectors, making her an invaluable asset as the company progresses with its innovative clinical programs.
“We are thrilled to have Shawnte on board to lead our Legal team,” shared Sean P. Bohen, M.D., Ph.D., the President and CEO of Olema Oncology. He emphasized the importance of her background in regulatory, commercial, and intellectual property matters, particularly as the company advances its late-stage palazestrant programs.
A Proven Track Record
Before joining Olema, Ms. Mitchell was Chief Legal Officer at Genomatica, where she managed extensive business transformation efforts and oversaw critical compliance initiatives. Her previous role at Zogenix as Executive Vice President, General Counsel, and Corporate Secretary further solidified her expertise in corporate governance, compliance, and operational strategies.
Additionally, she has held significant leadership positions at Aptevo Therapeutics, where she was responsible for corporate affairs and compliance. Ms. Mitchell is also actively involved in community service as a board member of Life Science Cares Bay Area.
Key Insights from Ms. Mitchell
Expressing her enthusiasm, Ms. Mitchell stated, “I am thrilled to join Olema during such pivotal times as the company aims to provide new treatment options for breast cancer patients.” Her eagerness to contribute to Olema's growth and development of cutting-edge therapies reflects her commitment to improving patient outcomes.
About Olema Oncology
Olema Oncology is at the forefront of transforming breast cancer treatment. Committed to excellence, the company focuses on developing novel treatments, including its lead candidate, palazestrant (OP-1250). This oral medication is currently in Phase 3 clinical trials and aims to enhance patient care in endocrine-driven cancers.
Located in San Francisco with facilities in Cambridge, Massachusetts, Olema is dedicated to pushing the boundaries of cancer therapy through innovation and research.
Contact Information
For media inquiries, please contact: Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
Email: media@olema.com
Frequently Asked Questions
What are Shawnte M. Mitchell's qualifications?
Shawnte M. Mitchell holds a B.S. in Biological Sciences from Stanford University and a J.D. from The George Washington University Law School, bringing over 20 years of industry experience.
What role will Shawnte M. Mitchell play at Olema Oncology?
Shawnte will serve as Chief Legal Officer and Corporate Secretary, overseeing legal functions and supporting corporate governance as the company develops its clinical programs.
What is Olema Oncology's primary focus?
Olema Oncology is dedicated to developing targeted therapies for breast cancer, particularly focusing on novel treatments like palazestrant for endocrine-driven cancer.
Where is Olema Oncology headquartered?
Olema Oncology is headquartered in San Francisco, with additional operations in Cambridge, Massachusetts.
How can I contact Olema for media inquiries?
For media inquiries, please contact Courtney O’Konek at media@olema.com.
